



ANNUAL REPORT 2022

Simris
GROUP



3 ABOUT SIMRIS GROUP

4 WORDS FROM THE CEO

6 OUR BUSINESS

8 FINANCIAL REPORTS

Management report 8

Income statement 12

Balance sheet 13

Report on changes in equity 15

Cash flow analysis 15

Notes 20

Audit report 28

30 THE BOARD OF DIRECTORS

31 MANAGEMENT

32 THE SHARE

ABOUT SIMRIS GROUP

The original concept for Simris was to extract EPA and DHA Omega-3 from microalgae, the actual source of these essential fatty acids – not fish! By switching to Omega-3 produced by microalgae on dry land, the vision was to relieve pressure on marine ecosystems by transforming an industry.

The fact is that one microalgae or cyanobacteria produces multiple high value compounds. The vision of the Simris Group of today is expanded to leverage this fact and provide Simris Operating Companies with a pipeline of novel compounds extracted from microalgae and cyanobacteria for sale across different industry sectors.

Considering the many thousand strains of cyanobacteria and microalgae that have evolved to thrive in every ecosystem it is maybe not so surprising that more and more people are turning to these microscopic miracles for solutions to many of the challenges facing our planet.

Within Simris Biologics we hold a library of more than 1,200 strains of cyanobacteria. We have already identified more than 5,000 novel, natural compounds from cyanobacteria in this library. Some compounds are showing activity that suggests potential for application within cosmetics, others anti-microbial, anti-fungal or anti-cancer activity, still others are exhibiting activity associated with pesticides, herbicides and plant growth stimulants. Compounds with other properties such as gelling agents or pigments or simply the protein within the biomass could have application in foods.

WORDS FROM THE CEO

When I joined Simris in May 2022 I was tasked by the Board to lead the transformation from an Omega-3 brand to a science-based, vertically integrated biologics company operating across multiple industry sectors. We have made significant progress during the past year, beginning with our acquisition of Cyano Biotech. This was achieved at the same time as building strong platforms for future sales, upgrading our production facility and strengthening the team.

At each step we have laid down the foundation upon which to build our long-term vision. The Simris of today is already a completely different business from the one we had this time last year. The renaming of the business, as Simris Group AB, marked a break from the past and clearly positions Simris closer to its goal to build a group of companies operating across multiple industry verticals and with a vastly lower environmental footprint than the industries of today.

We began our transformative journey with the strategic acquisition of Cyano Biotech (recently renamed Simris Biologics). This provided in-house R&D capabilities and our own library of more than 5,000 novel natural compounds showing potential in pharma, cosmetics, foods, nutrition supplements, and agriculture industries. Through continuous investment we will build an industry-leading team with the knowhow to deliver a pipeline of novel compounds to our Simris Group companies operating in relevant sectors. The acquisition also gave us immediate entry into the BioPharma sector through its patent-protected Antibody Drug Conjugate (ADC) technology platform. The market for ADCs, seen as the next generation of targeted cancer therapeutics, is growing rapidly and is expected to grow from its current level of over \$7bn in 2022 to more than \$22bn by 2030. Operating in this sector is transformative for Simris, as just 1kg of ADC payload extracted from cyanobacteria can be worth several million dollars. License deals with pharmaceutical companies are expected to bring significant revenue in the short- and medium-term through milestone payments and additionally in the longer term through sales of toxins as payloads, as well as royalties on sales of any ADC drugs reaching commercial use.

The next step was to reset the sales platforms based upon our internal strengths and capabilities and the current regulatory environment. With the value of a single license for an ADC payload potentially worth more than \$100m, combined with the fact that our platform provides the opportunity to make multiple license agreements, we invested heavily into further developing the science behind our product and our sales platform. Simris' agreement with Lonza Ltd serves as a robust verification of the potential within our platform, and we would be disappointed if, through this collaboration with Lonza, we did not sign our first license agreement within the next 12 months.



"With so much progress in such a short time having established capable platforms for research and development, production, and sales, I remain extremely excited about the future of the business and unlocking the immense potential it holds."

Historically, the primary purpose of Simris was to replace Omega-3 from fish with Omega-3 from microalgae grown on dry land. As fish do not produce Omega-3 (they simply accumulate it in their bodies by eating algae) there is no need for humans to raid the oceans and destroy marine ecosystems for this essential oil. Whilst the vision for the business is now much broader, we remain dedicated to this cause. Simris' original product could not be sold in Europe due to current European Union (EU) laws regulating food sources. This prevented us from using Omega-3 sourced from the specific algae we grew. After unsuccessfully fighting to get our product approved for three years, we decided to reformulate our product using an Omega-3 that comes from an alternative algal species that is EU approved as a food source. In planning the relaunch, we took the opportunity to significantly reduce the amount of external packaging used to further minimise our footprint. Sales of starter packs and refill packs began in Sweden in January 2023, and in the US in March. We have further plans to enter key EU markets, and to extend the range, in the second half of the year.

As part of its turnaround, Simris opened up a new revenue stream during the second half of 2021 and Q1 2022 through business to business (B2B) sales of its microalgae biomass to industry partners interested in the high quality and high levels of Fucoxanthin and Omega-3 in our biomass. Demand for algae as a source of specialised ingredients for foods, food supplements and cosmetic ingredients is growing globally. To be better positioned to take advantage of this opportunity, and to substantially improve the profitability of the Hammenhög site, the Management team proposed to the Board that we pause operations through Q4 (whilst energy costs are peaking and growth rates are lowest) to complete a major upgrade to the production facility. The goal was to double production capacity from the existing plant. Accordingly, through Q4 2022 and Q1 2023, the team at Hammenhög have stripped down and rebuilt photobioreactors, enhanced biosecurity to minimise risk of contamination, installed multiple new sensors monitoring growth conditions and installed a new system of energy efficient LED lights. The first bioreactors were restarted in January, whilst work continued on the other (larger) systems. By the end of March, we were able to report that the current crop is the

healthiest algal culture in the history of the company, and that with the rapid growth rates we are experiencing, we anticipate being able to produce at least double the average biomass grown historically over a 12-month period. This improvement not only provides the opportunity for more B2B sales than before but also ensures that the Hammenhög site can operate at profit. We will soon have all bioreactors operational and plan for the first commercial harvest in June. This will enable the first B2B sales to commence early in Q3 once the biomass has been dried and passed our strict quality control inspections.

With so much progress in such a short time and having established capable platforms for research and development, production, and sales, I remain extremely excited about the future of the business and unlocking the immense potential it holds.

I am grateful to my team for the incredible efforts they have made and for commitment they show every day. I am also grateful to have such strong support from our Board and in particular our Chairman, Steven Schapera, who is the strongest believer of all and who continues to back this belief through the funding facility agreed with a company he is associated with (The Brand Laboratories).

I would like to end by thanking you, our shareholders, for your continued belief in Simris and in our ability to complete our transformation process and build a highly profitable, industry leading biologics company.

Julian Read, CEO

Hammenhög, April 2023

OUR BUSINESS

Simris Group AB is a biologics company identifying high value, natural, biologically active compounds found in microalgae and cyanobacteria for applications in skincare, nutrition, and biopharmaceuticals. The company sustainably grows microalgae and cyanobacteria at industrial scale within its photobioreactor facility. Photosynthetic systems, such as those operated by Simris, consume CO₂ as the microorganisms grow, whilst cultivation conditions can be optimized for production of many commercially interesting high-value compounds.


Our vision for Simris is to build a global business, based upon compounds extracted from microalgae and cyanobacteria, that can eventually supersede petrochemical and synthetic chemistry-based industries. Simris will operate a vertically integrated business model from R&D, through to cultivation of biomass, extraction and refining of compounds, for sale either B2B or as consumer products across multiple industry verticals.

The graphic below is the blueprint for the business that we aim to build. The time frame to implement such an industry-defining blueprint is more than ten years. Simris will play a leading role in a future microalgae-based industry producing products, and materials for products, in a drastically more sustainable way than current industry. As an example, one microorganism contains multiple compounds that can be used in a multitude of industry sectors. The Simris Group will leverage this and provide

Operating Companies with a pipeline of novel compounds and materials for sale in different industry sectors.

Prior to the acquisition of Cyano Biotech (renamed Simris Biologics in February 2023), Simris was already operating two different business models, namely Nutritional Supplements (B2C) and Biomass for Food Ingredients (B2B). The acquisition of Cyano-Biotech not only brought us a highly experienced in-house R&D capability and a library of novel compounds that can be developed for different verticals in the future, but also two further business models. The first, and most lucrative is a biopharmaceutical business within the field of Antibody Drug Conjugate (ADC)* medicines. The second is a small operation providing Standards and Reagents sold to external laboratories that test for the presence of cyanobacterial toxins in water supplies.

SIMRIS GROUP



*ADC = Antibody Drug Conjugate: targeted cancer therapy and improved patient life quality



There are four key business operations within the Simris Group today:

SIMRIS BIOPHARMACEUTICALS: With a library of over 5,000 novel cyanobacterial compounds, Simris Biologics (a wholly owned subsidiary of Simris Group AB) has hits and leads for novel compounds showing antimicrobial, antiviral and anti-fungal activities. This provides the business with a pipeline of opportunities to develop new drugs in collaboration with those pharmaceutical companies seeking novel compounds with protected technology and, who like all companies, are under pressure to reduce their carbon emissions.

Simris Biologics' lead programme is its patent protected Antibody Drug Conjugate (ADC) payload platform. This offers drug developers not only a potent toxin, with a novel mode of action, but uniquely where CO₂ is consumed instead of emitted during the production of the drug.

Simris continues to invest in developing and protecting its ADC technology platform for which the business model is to sign license agreements with drug development companies. In February 2023, the Company signed a collaboration agreement with Lonza Ltd, who as Simris' Contract Development and Manufacturing Organisation (CDMO) gained the globally exclusive rights to promote Simris's ADC technology. Simris anticipates that the first license agreement will be made with the coming 12 months.

SIMRIS NUTRACEUTICALS: Simris Group AB (formerly Simris Alg AB), has historically sold a range of microalgae food supplements under the Simris brand and almost exclusively only in the USA due to regulatory restrictions in Europe. Following a relaunch at the beginning of 2023, of an Omega-3

product that can be sold globally, the company continues to drive Direct to Consumer (D2C) sales from its own e-commerce platform as well as via Amazon.com (in Sweden and the USA respectively) and other strategic sales channels such as pharmacy chains and health stores. A further roll out of our Omega-3 product to new European markets and a broader range of products will follow over the coming 12 months.

SIMRIS FOODS: In Q3 2021, Simris Group AB began Business to Business (B2B) sales of microalgae biomass to industrial partners interested in the high value fucoxanthin that it contained. Following the recent upgrade to the Hammenhög production facility, the company is experiencing record growth rates and now anticipates a doubling of its average historical harvest over the next year. Commercial harvesting of the current crop of algae is planned to begin late in Q2 2023, enabling sale of fresh biomass to B2B customers early in Q3 2023.

Simris has also developed a prototype of a fucoxanthin-rich oleoresin product that could be included in Food Supplements, Foods and Cosmetics. Such a product would initially need to be sold outside of the EU until such time as the species of algae currently grown at Hammenhög is approved by the European Food Safety Authority (EFSA) as a novel food.

SIMRIS DERMALOGICS: In collaboration with the Department of Biomedical Science at Malmö University, Simris Group AB has been conducting research into the beneficial effects of various microalgal and cyanobacterial compounds and extracts on skin. This work aims to identify novel compounds, and extracts, that can be protected under patent and sold under license to leading cosmetic companies.



FINANCIAL REPORTS

MANAGEMENT REPORT

The board and managing director of Simris Group AB (publ) (556841-9187) with registered office in Simrishamn hereby submit the annual and consolidated accounts for the financial year 2022. The annual accounts are drawn up in Swedish kronor (SEK). Amount in kSEK unless otherwise stated.

THE BUSINESS

Simris Group AB is a biologics company that identifies high-quality, natural, biologically active substances found in microalgae and cyanobacteria to extract for applications in skin care, nutrition and biopharmaceuticals. The company sustainably grows microalgae on an industrial scale within its photobioreactor facility where conditions are optimized for the production of these high-value compounds.

The wholly owned subsidiary Simris Biologics GmbH is active in research into biologically active substances found in microalgae and cyanobacteria, development of new technological platforms and cultivation of cyanobacteria on an R&D scale. Simris Biologics currently has a patent-protected technology that pharmaceutical companies can license to develop "Antibody Drug Conjugates" (ADC). The ADC field is seen as the future of cancer treatment.

The wholly owned subsidiary Simris Inc., is active in the import, distribution, marketing and sale of Simris Group's consumer products on the North American market.

THE SHARES AND OWNERSHIP

The share capital in Simris Group AB amounts to SEK 15,663,841 distributed over 180,302,520 shares, of which 180,302,520 B shares and 0 A shares. All shares have a quota value of SEK 0.0869. Each B share gives the right to one vote and each A share gives the right to two votes at the meeting. As of 31 December 2022, the company had 6,534 shareholders (6,709), of which the ten largest owned 29.52 percent of the share capital and votes (Euroclear). Simris Group's board chairman Steven Schapera was at the turn of the year the largest individual shareholder with 5.25 percent of the share capital and votes, followed by Bengt Johansson with 3.45 percent of the share capital and votes.

SIGNIFICANT EVENTS DURING THE FINANCIAL YEAR

- Magnus Högström takes office as interim CEO on January 1, 2022.
- Simris receives two B2B orders with a total value of approximately SEK 3.0m with delivery during the first quarter of 2022.
- Simris withdraws EFSA application for its Omega-3 oil.
- The shareholder of 250,000 A shares requests conversion to B shares.
- The board decides to carry out a rights issue of approx. SEK 25.1m, proposes that an extraordinary general meeting decides on a directed offset issue of approx. SEK 6.2m and the issuance of 3,500,000 warrants to the future CEO. An extraordinary general meeting is held on 8 April and decides according to the board's proposal.

- Simris publishes an investor memorandum ahead of the rights issue, which is oversubscribed and provides the company with approx. SEK 25.1m before issue costs.
- Julian Read takes over as CEO on 16 May 2022.
- The annual general meeting was held on 25 May 2022 in Simri's premises in Hammenhög.
- CEO Julian Read presents a CEO letter in which Simris' new acquisition-driven strategy is communicated.
- Simris acquires all shares in the German company Cyano Biotech GmbH and takes its first step towards BioPharma. In connection with this, a directed issue of approx. 3.9 million B shares is made to the sellers as part of the purchase price.
- A company related to Chairman of the Board Steven Schapera is issuing a flexible financing facility of 1 million EUR.

FINANCIAL DEVELOPMENT

Net sales and profit

Net sales amounted to kSEK 4,080 (6,137). Operating profit amounted to kSEK -24,657 (-28,928) and the result before tax amounted to kSEK -25,766 (-28,343). The reduction in net sales consists of reduced sales of biomass B2B.

Financial standing

At the end of the financial year, the group's cash and cash equivalents amounted to kSEK 3,994 (961). The cash flow from current operations during the year amounted to kSEK -18,188 (-18,137). The equity ratio as of December 31, 2022 was 12 percent, compared to 62 percent on December 31, 2021.

Investments

The reported value of Simris Group's fixed assets amounted to kSEK 178,316 (23,426) at the end of the financial year. The total investments in fixed assets during the year amounted to kSEK 22,382 (253). This year's investments are in principle fully linked to the acquisition of Cyano Biotech GmbH which affected the treasury by kSEK -10,091, see more details in note 17.

PERSONNEL AND ORGANIZATION

The average number of employees amounted to 8 (12) during the financial year.

FORSKNING OCH UTVECKLING

Through the acquisition of Cyano Biotech GmbH (subsequently renamed Simris Biologics GmbH), Simris gained its own research and development organization together with new relationships within the academic world. Simris' two Chief Science Officers oversee all research and development activities within the Simris Group and through collaborations with academic, industrial research institutes and companies.

Research and development is mainly within new biologically active substances. In the future, Simris Group intends to strengthen development activities, primarily through collaborations with leading researchers and industrial partners.

ENVIRONMENT

Simris Group's operations explicitly aim to replace unsustainable raw materials, products and production methods with new, environmentally superior alternatives based on nature.

The facility in Hammenhög is run with great care for the environment and a stated ambition to be at the forefront of circular economy and industrial symbiosis. The electricity comes exclusively from renewable energy production. Heating takes place with district heating from the neighbouring company Skånefrö/BIO-AGRO Energy, which has received several awards for its process of converting residual biomass into bio pellets for district heating. The carbon dioxide used in the cultivations is a natural residual product from the fermentation of wheat at Absolut Vodka's distillery in Nöbbelöv. The algae bind this green carbon dioxide during growth and convert it into oxygen through photosynthesis, which means favourable climate effects. The facility has a control system and algorithms for 24-hour regulation, which significantly lowers energy consumption compared to industry standards. When there is insufficient natural sunlight for optimal growth, energy-saving LED technology is exclusively used. Furthermore, continuous improvement work is underway to identify initiatives for environmental improvement measures and processes.

CERTIFICATIONS

Simris Group's facility in Hammenhög, its manufacturing process and its quality management system have been certified by Lloyd's Register Quality Assurance (LRQA) in accordance with Swedish Self-Care's criteria Safe dietary supplements for consumers, with certificate no. GBG6020202.

OPTION PROGRAM

Simris Group had five outstanding option programs at the end of the year. The conditions for all warrants have been recalculated according to the new issues carried out after the warrants were issued up to and including the reporting period.

Series 2019/1 consists of 43,438 warrants that were issued to employees in the company in May 2019. The options have a term of five years and for each option 1.45 B shares can be subscribed at a price of SEK 4.44 per share.

Series 2021/2024:S consists of 2,000,000 warrants that were issued to the board in May 2021. The options have a term of three years, and each option gives the right to subscribe for 1.34 B shares at the price of SEK 1.42. Exercising outstanding options corresponds to a dilution of the share capital by 1.5 percent.

Series 2021/2024:L consists of 1,820,000 warrants that were issued in May 2021 to senior executives and employees in the company. The options have a term of three years, and each option gives the right to subscribe for 1.34 B shares at the price of SEK 1.42. Exercising outstanding options corresponds to a dilution of the share capital by 1.4 percent.

Series 2022/1 consists of 1,750,000 warrants and was issued to the company's CEO in May 2022. The warrants have a term of three years, and each warrant gives the right to subscribe for 1.34 B shares at a price of SEK 0.91 per share. Exercising outstanding options corresponds to a dilution of 1.3 percent.

Series 2022/2 consists of 1,750,000 warrants and was issued to the company's CEO in May 2022. The warrants have a term of two years, and each warrant gives the right to subscribe for 1.34 B shares at a price of SEK 1.42 per share. Exercising outstanding options corresponds to a dilution of 1.3 percent.

Full utilization of all outstanding warrants at the end of the period corresponds to a dilution of 5.5 percent.

RISKS AND UNCERTAINTY FACTORS

Simris Group's operations, financial position and results can be affected by a number of risks and uncertainty factors. The company works continuously to identify and manage the various types of risks to which the business is exposed.

Market risk for consumer products

Simris Group's business in consumer products is dependent on consumer demand. There are large differences in consumer attitudes towards health products and omega-3 in different markets around the world. Despite extensive research on the importance of omega-3 EPA and DHA and clinically proven health effects, negative studies do receive media coverage, which can negatively affect opinion and thus sales. A general downturn in the omega-3 supplement market, investments in the wrong markets and lack of consumer acceptance could have a negative impact on Simris Group's earnings, growth and results.

Competitors

Competition in the Antibody Drug Conjugates (ADC) payloads business area is considered to be low. Having invented the technology, Simris is currently the only company in the world that produces "ADC payloads" in this way and the company's patents constitute a significant barrier for competitors to enter this field without obtaining a license from the Simris Group.

Within Novel Foods, Simris Group finds itself in a fundamentally favourable competitive situation, but there is a risk that other players will offer similar raw materials in the future. In terms of consumer products, the number of omega-3 products from algae has increased significantly in recent years, and it is important that Simris Group can maintain its unique positioning in the premium segment. In the long term, increased competition may lead to reduced growth and reduced market shares, which may have a negative effect on Simris Group's operations, future growth, results, and financial position.

Trademark

Since Simris Group manufactures consumer goods, success depends on the ability to gain and maintain consumer trust in the safety, effectiveness, and quality of the products. Success also depends on the ability to create and maintain brand awareness for one's products, as well as to maintain reputation. Simris Group has chosen to position the brand in a pronounced premium segment, and success is dependent on the products maintaining a higher quality than the safety and quality standards that exist on the market and the company's ability to communicate the uniqueness of the products.

The company's expansion

Simris Group's vision is to build a global business that sells products based on substances extracted from microalgae and cyanobacteria and that are sold across several industry verticals. Each species of microalgae and cyanobacteria produces several different high-value substances that together have applications in almost every industry. The blueprint for the Simris of the future is for a company that grows many different species, uses different production techniques and, in the same place, extracts and refines several substances from the same biomass. This ensures the most environmentally friendly and most cost-effective production process.

In order to achieve the company's vision, mergers and acqui-

sitions will form a central part of Simris Group's strategy. Target companies will need to deliver a combination of; a positive

EBITDA, access to new product categories, new geographies, new capabilities and competences, new intellectual property rights and expanded production capacity.

In the short term, the growth of the business will mainly come from the sale of nutritional supplements under the Simris brand, B2B sales of biomass to industrial partners, sales of cyanobacterial standards for use in laboratories tasked with monitoring water quality, and licensing agreements with pharmaceutical companies developing a new ADC -drugs.

Success in implementing its strategy and growth of operations is dependent on Simris Group's ability to attract the necessary resources, including capital, and to build an organization that is capable of growing rapidly and creating profitability.

Legislation and authority decisions

Simris Group's products are subject to widely differing regulations and legislation in different markets.

Products within BioPharma are strongly regulated by each country's regulatory framework for pharmaceutical products. Simris Group will license its technology platform to a drug development partner who will have sole responsibility for the registration and approval process of the drug they develop in each regulatory territory. Simris Group will be required to demonstrate that its Payloads are produced in accordance with Good Manufacturing Process as part of the regulatory approval process.

The products within the Novel Foods business area are covered by each country's regulations for food, and especially new food ingredients. Here, the conditions in markets such as the USA and Great Britain (after Brexit) are significantly more favourable than within the EU. Consumer products are also covered in many markets such as Sweden and within the EU by food legislation, while other countries have special rules for dietary supplements. The regulatory barriers to entry in different markets vary greatly. Legislation, regulations and authority management in both Sweden and other countries can constitute obstacles and cause increased costs and significant delays in the establishment of Simris Group's products on the market.

The type of advanced skin care ingredients Simris Group is developing requires some documentation, but neither the US nor the EU require specific regulatory approvals.

Research and Development

Simris Group conducts a number of research and development projects with the goal of developing new products, both under its own auspices and in collaboration with various partners. There is always a risk that projects will suffer delays or not achieve the desired results. There is also no guarantee that projects or collaborations result in new products that can be launched, or that Simris Group gets exclusive rights to the results. Simris Group manages the risks above all by conducting parallel projects with different development horizons and levels of innovation.

Intellectual property rights and internal know-how

Simris Group strives to protect its intellectual property rights through trademark registrations and agreements in the countries where the group operates or intends to operate.

Simris Group currently holds two patents covering the production of non-ribosomal peptides from cyanobacteria for use as

ADC payloads and for the cyanobacterial toxin, microcystin, as a first class of ADC payload. New patent applications in the ADC field will be filed in due course as science advances.

Ongoing research in the skin care area aims to identify new individual substances and/or extracts with proven activity that benefits the skin. The group will apply for patent protection for all new products arising from this work.

Certain parts of the cultivation process are protected as a trade secret. Simris Group's business secrets may become known through information leakage or in other ways. Corresponding trade secrets and similar production methods may be developed by competitors, who may launch similar, competing products.

Technical risks during operation

The technology for cultivation and downstream processes has been verified through continuous operation on an industrial scale since 2016. Experience with operational stability during continuous cultivation for a long time is therefore very good. Restarting the production process with new algae cultures, which according to plan must be done at regular intervals, may, however, require more frequent or more irregular intervals. New algae strains that the company works with may require some running-in to establish optimal conditions. This means periodically lower productivity. Climate change such as longer periods of drought or significantly increased temperatures may require additional investments in own water supply and cooling.

Dependence on key people

Simris Group is a small organization that is highly dependent on the knowledge, experience and commitment of key personnel. Identifying and attracting employees with the right characteristics and skills and retaining key people are crucial for the company's success and ability to deliver according to plan

Suppliers

Manufacturing is dependent on a number of suppliers in the downstream chain. There is a risk that the business could be negatively affected if subcontractors do not fulfil their commitments. Changing suppliers can cause delays and/or increased costs. The company is therefore reviewing its subcontractor chain to reduce dependence on subcontractors.

Disputes, claims, investigations and proceedings

Simris Group may become involved in disputes within the framework of normal business operations and risks being subject to claims in legal processes concerning contracts, product liability, or alleged deficiencies in deliveries of goods and services. Such claims can involve large sums and significant litigation costs.

Liquidity risk

Simris Group is in the start-up phase and still lacks sufficient own earning power to cover the costs of the business through sales revenue. Simris Group needs additional external financing in 2023 in order to continue its operations and implement its growth plans. There is a risk that new capital cannot be obtained when needed, that new capital cannot be obtained on satisfactory terms, or that acquired capital is not sufficient to finance the business in accordance with established development plans and objectives.

Currency risks

Simris Group's production costs and sales revenue are in different currencies. Production costs are dominated by SEK, EUR and GBP. Sales revenue is mainly in SEK, EUR and USD but may have significant elements of foreign currencies. Simris Group is therefore exposed to exchange rate risks

FUTURE PROSPECTS

Simris Group is still in the development phase with ongoing product launches and several development projects that have not yet reached the market phase. The sales revenue is not sufficient to finance either the current operation or planned development and marketing efforts.

At the moment, the business has insufficient funding to cover the capital requirement until the end of the business year 2023, thus there is a significant uncertainty factor regarding the company's ability to continue operating. The future of the business depends on sufficient capital being acquired to finance ongoing operations, research and development, marketing, and recruitment. Although there is a risk that the company will not be able to obtain the necessary financing, the board is confident that it can secure the financing necessary to continue building the business in the coming years.

The board will present a proposal to the annual general meeting for a renewed authorization to carry out new issues, with or without preferential rights for existing shareholders. The purpose is to be able to procure capital for the company to secure operations for the following business year and to carry out market initiatives

and investments in development and production capacity. The board assesses that any targeted issues can also have favourable effects on the company's ownership structure and development ability.

The situation between Ukraine and Russia has no direct impact on the company, suppliers or customers as operations are not conducted in the region. On the other hand, the company is affected by increased prices from suppliers, especially for energy.

PROPOSAL FOR DISPOSAL OF PROFITS

The board proposes that available funds:	Amount in SEK
premium fund	73,051,265
balanced result	-43,165,829
the year's results	-19,891,948
Total	9,993,488
Disposed of in such a way that: in a new account is transferred	9,993,488
Total	9,993,488

Regarding the group's results and position in general, reference is made to the subsequent income statement and balance sheet, cash flow analysis and report on changes in equity, with associated additional information.

MULTI-YEAR OVERVIEW, GROUP

	2022	2021	2020	2019	2018
Net revenue (kSEK)	4,080	6,137	2,166	1,743	762
Operating result / EBIT (kSEK)	-24,657	-28,928	-23,694	-24,626	-22,671
Result before tax (kSEK)	-25,766	-28,343	-25,537	-27,007	-23,989
Cash flow from operating activities (kSEK)	-17,961	-18,137	-19,485	-17,316	-22,269
Equity (kSEK)	23,034	18,221	47,423	34,996	39,782
Earnings per share (SEK)	neg.	neg.	neg.	neg.	neg.
Earnings per share after full dilution (SEK)	neg.	neg.	neg.	neg.	neg.
Equity per share (SEK)	0.13	0.23	0.60	1.62	2.96
Equity per share after full dilution (SEK)	0.13	0.23	0.60	1.62	2.96
Number of shares, average	142,397,290	78,543,868	42,474,038	11,766,327	10,464,848
Number of shares, end of period	180,302,520	78,547,046	78,540,690	21,536,688	13,443,756
Number of shares after full dilution*	180,302,520	78,547,046	78,540,690	21,536,688	13,443,756
Solidity (%)	12	62	83	67	80
Balance sheet total (kSEK)	185,712	29,201	57,065	52,207	49,836
Cash at the end of period (kSEK)	3,994	961	16,512	7,859	4,416
Cash liquidity (%)	21	27	279	70	96
Average number of employees	8	12	12	16	15

*Simris Group has five outstanding warrant programs. Dilution effects have not been taken into account for any of the programs for the full year 2022, as the closing price for Simris Group's share is lower than the subscription price in all programs. Full utilization of all outstanding warrants at the end of the period corresponds to a dilution of 5.5 percent.

INCOME STATEMENT, GROUP

(kSEK)	Note	2022-01-01- 2022-12-31	2021-01-01- 2021-12-31
Net revenue		4,080	6,137
Change of finished goods and work in progress		-3,676	-5,136
Activated work for own account		0	230
Other operating income	2	646	392
		1,050	1,623
OPERATING COSTS			
Raw materials and consumables		-1,146	-3,298
Other external expenses	3	-10,865	-12,316
Personnel expenses	4	-7,044	-9,134
Depreciation and amortization		-6,652	-5,803
Total operating costs		-25,707	-30,551
OPERATING RESULTS		-24,657	-28,928
FINANCIAL POSTS			
Interest income and similar income items		0	1,201
Interest costs and similar income items		-1,109	-616
Total financial items		-1,109	585
RESULT BEFORE TAX		-25,766	-28,343
Deferred tax		1,036	-4
Tax		308	-9
RESULTS OF THE YEAR		-24,422	-28,356

BALANCE SHEET, GROUP

ASSETS (kSEK)	Note	2022-12-31	2021-12-31
FIXED ASSETS			
Intangible assets			
Balanced expenses for development work and similar work	5	0	0
Patents and trademarks and similar rights	6, 17	155,899	0
Total intangible fixed assets		155,899	0
Tangible fixed assets			
Land and buildings	7	11,734	12,424
Equipment, tools and installations	8	10,683	10,932
Total tangible fixed assets		22,417	23,356
Financial assets			
Deferred tax claim		0	70
TOTAL FIXED ASSETS		178,316	23,426
CURRENT ASSETS			
Inventory etc			
Raw materials and consumables		387	95
Goods under production		0	2,661
Finished goods and goods for sale		1,870	592
Total inventory		2,257	3,348
Receivables			
Accounts receivable		23	64
Other claims		922	664
Prepayments and accrued income	10	200	738
Total current receivables		1,145	1,466
Cash and bank balances		3,994	961
TOTAL CURRENT ASSETS		7,396	5,775
TOTAL ASSETS		185,712	29,201

EQUITY AND LIABILITIES (kSEK)	Note	2022-12-31	2021-12-31
EQUITY			
Share capital	11	15,664	6,824
Other contributed capital		93,581	74,295
Other equity incl. the year's results		-86,211	-62,898
Total equity		23,034	18,221
LIABILITIES			
Provisions			
Deferred tax		47,331	87
Total provisions		47,331	87
Long-term liabilities			
Liabilities to credit institutions	12	1,559	1,808
Other debts		89,921	0
Total long-term liabilities		91,480	1,808
Current liabilities			
Liabilities to credit institutions		570	1,321
Accounts payable		939	1,100
Tax debts		19	0
Other debts		21,143	4,621
Accrued costs and prepaid income	13	1,196	2,043
Total short-term liabilities		23,867	9,085
TOTAL LIABILITIES AND PROVISIONS		162,678	10,980
TOTAL EQUITY AND LIABILITIES		185,712	29,201

REPORT ON CHANGES IN EQUITY, GROUP

(kSEK)	Share capital	Other contributed capital	Other equity incl. the year's results
Amount at the beginning of the year	6,824	74,295	-62,898
New issue (incl. issue costs), subscription rights, convertible loan	8,840	19,181	
Subscription options		105	
Conversion difference			1,109
This year's results			-24,422
AMOUNT AT THE END OF THE YEAR	15,664	93,581	-86,211

CASH FLOW ANALYSIS, GROUP

(kSEK)	Note	2022	2021
Operating results		-24,657	-28,928
Adjustment for items not included in the cash flow:			
Depreciation and amortization		6,652	5,803
Interest income and similar income items		0	1,201
Interest costs and similar income items		-1,109	-616
Other		1,153	-1,059
Cash flow from operating activities before changes in working capital		-17,961	-23,599
Increase/decrease inventory		1,091	5,468
Increase/decrease in operating receivables		321	1,304
Increase/decrease operating liabilities		-1,639	-1,310
Cash flow from current operations		-18,188	-18,137
Investments in intangible fixed assets	17	-20,295	-253
Investments in tangible fixed assets		-2,087	0
Cash flow from investment activities		-22,382	-253
New issues		28,022	10
Option premiums		105	191
Borrowings		23,476	3,500
Amortization of debt		-8,000	-862
Cash flow from financing activities		43,603	2,839
The year's cash flow		3,033	-15,551
Liquid funds at the beginning of the year		961	16,512
LIQUID FUNDS AT THE END OF THE YEAR		3,994	961

INCOME STATEMENT, PARENT COMPANY

(kSEK)	Note	2022-01-01- 2022-12-31	2021-01-01- 2021-12-31
Net sales		3,060	5,887
Change of finished goods and goods under manufacture		-2,357	-4,531
Activated work for own account		0	230
Other operating income	2	258	392
		961	1,978
OPERATING COSTS			
Raw materials and consumables		-1,016	-3,298
Other external expenses	3	-9,751	-10,504
Personnel costs	4	-6,093	-9,134
Depreciation and impairment of tangible and intangible fixed assets		-2,872	-5,788
Total operating costs		-19,732	-28,724
OPERATING RESULTS		-18,771	-26,746
FINANCIAL POSTS			
Write-down of group company receivables		-2,868	-13,084
Interest income and similar income items		778	554
Interest costs and similar income items		-691	-616
Exchange rate differences		1,673	838
Total financial items		-1,108	-12,308
PROFIT BEFORE TAX		-19,879	-39,054
Deferred tax		-13	-10
Tax		0	0
RESULTS OF THE YEAR		-19,892	-39,064

BALANCE SHEET, PARENT COMPANY

ASSETS (kSEK)	Note	2022-12-31	2021-12-31
FIXED ASSETS			
Intangible fixed assets			
Balanced expenses for development work and similar work	5	0	0
Patents and trademarks and similar rights	6	0	0
Total intangible fixed assets		0	0
Tangible fixed assets			
Land and buildings	7	11,733	12,424
Equipment, tools and installations	8	8,825	10,926
Total tangible fixed assets		20,558	23,350
Financial assets			
Shares and shares in group companies	9, 17	113,887	9
TOTAL FIXED ASSETS		134,445	23,359
CURRENT ASSETS			
Inventory, etc.			
Raw materials and consumables		387	95
Goods under production		0	2,661
Prepared goods and goods for sale		352	84
Total inventory		739	2,840
Current receivables			
Accounts receivable		4	3
Other Claims		754	664
Loan receivable group company		1,117	0
Prepayments and accrued income	10	50	701
Total current receivables		1,925	1,368
Cash and bank balances		3,490	753
TOTAL CURRENT ASSETS		6,154	4,961
TOTAL ASSETS		140,599	28,320

EQUITY AND LIABILITIES (kSEK)	Note	2022-12-31	2021-12-31
EQUITY			
Restricted equity			
Share capital	11	15,664	6,824
Fund for development expenses		0	0
Total tied up equity		15,664	6,824
Unrestricted equity			
Premium fund		73,051	53,870
Balanced gain or loss		-43,166	-4,207
This year's results		-19,892	-39,064
Total unrestricted equity		9,993	10,599
TOTAL EQUITY		25,657	17,423
LIABILITIES			
Provisions			
Deferred tax		101	87
Total provisions		101	87
Long-term liabilities			
Liabilities to credit institutions	12	1,559	1,808
Other debts		89,921	0
Total long-term liabilities		91,480	1,808
Current liabilities			
Liabilities to credit institutions		570	1,321
Accounts payable		908	1,067
Other debts		20,754	4,598
Accrued costs and prepaid income	13	1,129	2,016
Total short-term liabilities		23,361	9,002
TOTAL LIABILITIES		114,942	10,897
TOTAL EQUITY AND LIABILITIES		140,599	28,320

REPORT ON CHANGES IN EQUITY, PARENT COMPANY

(kSEK)	Share capital	Fund for development expenses	Premium fund	Balanced result	This year's results
Amount at the beginning of the year	6,824	0	53,870	-4,207	-39,064
Disposition according to decision of the annual general meeting				-39,064	39,064
New issues	8,840		19,181		
Subscription options				105	
This year's results					-19,892
AMOUNT AT THE END OF THE YEAR	15,664	0	73,051	-43,166	-19,892

NOTES

NOTE 1 | ACCOUNTING AND VALUATION PRINCIPLES

General information

The annual report has been prepared in accordance with the Annual Accounts Act and BFNAR 2012:1 Annual accounts and consolidated accounts (K3).

Unless otherwise stated, short-term receivables are valued at the lower of their acquisition value and the amount with which they are estimated to be settled. Long-term receivables and long-term liabilities are valued after the first valuation at amortized cost. Other liabilities and provisions are valued at the amounts with which they are estimated to be settled. Other assets are reported at acquisition value unless otherwise stated.

Receivables and liabilities in foreign currency have been valued at the exchange rate on the balance sheet date. Exchange rate gains and losses on operating receivables and operating liabilities are reported in operating profit, while exchange rate gains and losses on financial receivables and liabilities are reported as financial items.

Group accounts

The consolidated accounts are prepared according to the acquisition method. The consolidated accounts cover the parent company and its subsidiaries. Subsidiaries are companies in which the parent company, directly or indirectly, has a controlling influence. In the normal case, this refers to companies where the parent company holds more than 50 percent of the votes. The consolidated accounts include the subsidiaries from the day the group obtains controlling influence until the day it no longer exists. The subsidiaries' accounting principles are consistent with the group's accounting principles in general.

In the consolidated accounts, the closing appropriations of the group companies are omitted and are included in the reported profit after deduction for deferred tax. This means that the group companies' untaxed reserves in the group's balance sheet are distributed between deferred tax liability and equity.

Public contributions

Public grants are reported at fair value when there is reasonable certainty that the grant will be received and that the company will fulfil all related conditions. Public contribution that relates to expected costs is reported as prepaid income. The grant is recognized as income in the period when the costs are incurred that the public grant is intended to compensate and that there is reasonable certainty that the grant will be received for these costs. Public grants are reported as other operating income.

Income statement

Revenues have been recorded at the fair value of what has been received or will be received and reported to the extent that it is likely that the financial benefits will be appropriated to the company and the income can be calculated reliably.

Intangible assets

The company reports internally developed intangible fixed assets according to the capitalization model. This means that all expenses relating to the production of an internally developed intangible fixed asset are capitalized and written off during the asset's estimated useful life, under the conditions that the criteria in BFNAR 2012:1 are met.

Fixed assets

Intangible and tangible fixed assets are reported at acquisition value less accumulated depreciation according to plan and any write-downs.

Depreciation takes place linearly over the expected period of use, taking into account significant residual value. The following depreciation rate is applied:

Intangible assets

Patents and trademarks and similar rights	10–15 years
Balanced expenses	5 years

Tangible fixed assets

Buildings	20–50 years
Equipment, tools and installations	5–20 years

Component breakdown

Tangible fixed assets have been divided into components when the components are significant and when the components have significantly different useful lives. When a component of a fixed asset is replaced, any remaining part of the old component is retired, and the cost of the new component is capitalized. Expenditures for ongoing repairs and maintenance are reported as costs.

Lease agreement

The company reports all leasing agreements as operational, as the existence of financial leasing agreements is immaterial.

Inventory

The inventory has been valued at the lower of its acquisition value and its net sales value on the balance sheet date. Net sales value refers to the goods' calculated sales price less sales costs. The chosen valuation method means that obsolescence in the inventory has been taken into account.

Income taxes

Total tax consists of current tax and deferred tax. Taxes are reported in the income statement, except when the underlying transaction is reported directly against equity, in which case the associated tax effects are reported in equity.

Current tax

Current tax refers to income tax for the current financial year as well as the part of the previous financial year's income tax that has not yet been reported. Current tax is calculated based on the tax rate that applies as of the balance sheet date.

Deferred tax

Deferred tax is income tax that refers to future financial years as a result of past events. Accounting takes place according to the balance sheet method. According to this method, deferred tax liabilities and deferred tax receivables are reported on temporary differences that arise between the book and tax values of assets and liabilities as well as for other tax deductions or deficits.

Deferred tax assets are netted against deferred tax liabilities only if they can be paid with a net amount. Deferred tax is calculated based on the current tax rate on the balance-the day. Effects of changes in current tax rates are recognized in

the income statement in the period the change is legislated. The deferred tax asset is reported as a financial fixed asset and the deferred tax liability as a provision.

Deferred tax receivables relating to loss deductions or other future tax deductions are reported to the extent that it is likely that the deductions can be offset against future tax surpluses. Due to the relationship between accounting and taxation, the deferred tax liability attributable to untaxed reserves is not separately accounted for.

Simris Group AB's accumulated tax deficit on the balance sheet date amounts to SEK 197m.

Simris Group currently assesses that conditions according to the K3 regulations for booking deferred tax receivables attributable to tax loss carry-forwards are not met.

Compensation to employees

Remuneration to employees consists of salary, social security contributions, paid holiday, paid healthcare and bonus. Compensation is reported as a cost and a liability when there is a legal or informal obligation to pay compensation.

Significant estimates and judgments

In connection with the preparation of the financial reports, the board and company management must make assessments and assumptions that affect balance sheet and income statement items as well as related information. The estimates for accounting purposes that result from these will, by definition, rarely correspond to the actual result.

Current valuation of the company's assets assumes that the existing business plan will be realized. The estimates and assump-

tions that entail a significant risk of significant adjustments in reported values for assets and liabilities during the next financial year are outlined below.

Intangible and tangible fixed assets

The group determines the estimated useful life and associated depreciation for intangible and tangible fixed assets. These estimates are based on estimated expected useful life. The useful life and estimated residual values are tested every balance sheet date and adjusted if necessary.

Stock

The group's sales are under construction and in order to be able to respond to growing demand within reasonable lead times there is a significant stock of raw materials, work in progress and finished products. There is a risk that raw materials, work in progress and manufactured products become unusable before further processing and/or sale can take place. In the financial statements, write-downs for obsolescence are made based on an obsolescence ladder that takes into account different customers' requirements for durability. Determining the need for impairment is a significant and difficult assessment issue.

Deferred tax attributable to loss deductions

As of the balance sheet date, the company had tax-related loss deductions from business activities, which are estimated to amount to SEK 197 million. These loss deductions have not been assigned a value in the balance sheet as historically the company has not previously reported any tax surplus.

NOTE 2 | OTHER OPERATING INCOME

(kSEK)	The group		The parent company	
	2022	2021	2022	2021
State support for short-term layoffs	0	-14	0	-14
Other incomes	646	406	258	406
TOTAL	646	392	258	392

NOTE 3 | LEASES AND RENTS

The year's leasing fees regarding leasing agreements and rents amount to kSEK 233 (684) and kSEK 73 (684) for the parent company. Future lease payments, for non-cancellable leases, are due as follows:

(kSEK)	The group		The parent company	
	2022	2021	2022	2021
Leasing fees within one year	331	0	127	0
Leasing fees later than one year but within five years	276	0	276	0
Leasing fees later than five years	0	0	0	0
TOTAL FUTURE LEASE FEES AND RENTS	607	0	403	0

NOTE 4 | EMPLOYEES AND PERSONNEL COSTS

Average number of employees	The group		The parent company	
	2022	2021	2022	2021
Women	3	7	3	7
Men	5	5	4	5
TOTAL AVERAGE NUMBER OF EMPLOYEES	8	12	7	12

Salaries and other remuneration (kSEK)	The group		The parent company	
	2022	2021	2022	2021
CEO	1,481	526	1,481	526
Management team	461	567	461	567
Other employees	3,237	5,428	2,451	5,428
Board fees (see below)	324	360	324	360
Other remuneration to the board (see below)	0	0	0	0
TOTAL WAGES AND OTHER REMUNERATION	5,503	6,881	4,717	6,881

Social costs (kSEK)	The group		The parent company	
	2022	2021	2022	2021
Pension costs CEO	209	248	209	248
Pension costs management group	47	47	47	47
Pension costs other employees	103	221	103	221
Other social security contributions according to law and agreement	1,662	1,908	1,497	1,908
TOTAL SOCIAL COSTS	2,021	2,424	1,856	2,424
TOTAL WAGES, OTHER REMUNERATION AND SOCIAL COSTS	7,524	9,305	6,573	9,305

Julian Read took office as CEO May 16, 2022.

Board member Magnus Högström was acting CEO from January 1, 2022, to and including May 15, 2022.

A company wholly owned by Christoffer Tell has received SEK 1,080,000 in fees for the CFO assignment during 2022.

Remuneration to the board (kSEK)	2022			2021		
	Board fee	Other compensation	Total	Board fee	Other compensation	Total
Steven Schapera, chairman from 2021-05-07	140	0	140	93	0	93
Robert Quandt, board member from 2021-05-07	70	0	70	47	0	47
Frank Puccio, board member from 2021-05-07	70	0	70	47	0	47
Peter Nählstedt, board member from 2021-05-07 to 2021-06-16	0	0	0	8	0	8
Magnus Högström, board member from 2019-12-19	44	0	44	70	0	70
Johan Jörgensen, chairman from 2019-11-21 to 2021-05-07	0	0	0	47	0	47
Anders Frostensson, board member from 2019-05-08 to 2021-05-07	0	0	0	25	0	25
Nils Andersson, board member from 2019-05-08 to 2021-05-07	0	0	0	25	0	25
TOTAL WAGES AND OTHER REMUNERATION	324	0	324	360	0	360

At the annual general meeting on May 25, 2022, it was decided that board fees for ordinary members should amount to kSEK 70/year (70) and fees for the chairman of the board should amount to kSEK 140/year (140).

NOTE 5 | BALANCED EXPENSES FOR DEVELOPMENT AND SIMILAR WORKS

(kSEK)	The group		The parent company	
	2022	2021	2022	2021
Initial acquisition values	4,916	4,663	4,916	4,663
Purchases	0	253	0	253
Scrapping	-4,916	0	-4,916	0
OUTGOING ACCUMULATED ACQUISITION VALUE	0	4,916	0	4,916
Entering depreciation	-4,916	-2,163	-4,916	-2,163
Write-downs for the year	4,916	0	4,916	0
Scrapping	0	-2,663	0	-2,663
This year's depreciations	0	-90	0	-90
OUTGOING ACCUMULATED DEPRECIATION	0	-4,916	0	-4,916
OUTGOING ACCOUNTED VALUE	0	0	0	0

NOTE 6 | PATENTS AND TRADEMARKS AND SIMILAR RIGHTS

(kSEK)	The group		The parent company	
	2022	2021	2022	2021
Initial acquisition values	328	328	328	328
Purchases	159,442	0	0	0
Scrapping	-328	0	0	0
OUTGOING ACCUMULATED ACQUISITION VALUE	159,442	328	328	328
Ingoing depreciation	-328	-328	-328	-328
Scrapping	328	0	0	0
This year's depreciations	-3,543	0	0	0
OUTGOING ACCUMULATED DEPRECIATION	-3,543	-328	-328	-328
OUTGOING ACCOUNTED VALUE	155,899	0	0	0

NOTE 7 | LAND AND BUILDINGS

(kSEK)	The group		The parent company	
	2022	2021	2022	2021
Initial acquisition values	16,370	16,370	16,370	16,370
Purchase	0	0	0	0
OUTGOING ACCUMULATED ACQUISITION VALUE	16,370	16,370	16,370	16,370
Ingoing depreciation	-3,945	-3,255	-3,945	-3,255
This year's depreciations	-690	-690	-690	-690
ENDING ACCUMULATED DEPRECIATION	-4,636	-3,945	-4,636	-3,945
OUTGOING ACCOUNTED VALUE	11,734	12,424	11,734	12,424

NOTE 8 | INVENTORIES, TOOLS AND INSTALLATIONS

(kSEK)	The group		The parent company	
	2022	2021	2022	2021
Initial acquisition values	23,473	23,473	23,436	23,436
Purchases	2,129		81	
Scrapping	-47	0	0	0
OUTGOING ACCUMULATED ACQUISITION VALUE	25,555	23,473	23,517	23,436
Ingoing depreciation	-12,541	-10,183	-12,510	-10,165
Exchange rate difference	46	2	0	0
Write-downs for the year	41	0	0	0
Scrapping	0	-130	0	-130
This year's depreciations	-2,418	-2,230	-2,182	-2,215
OUTGOING ACCUMULATED DEPRECIATION	-14,872	-12,541	-14,692	-12,510
OUTGOING ACCOUNTED VALUE	10,683	10,932	8,825	10,926

NOTE 9 | SHARES AND SHARES IN GROUP COMPANIES

Name	Currency code	Organisation no	Seat	Share of capital, %	Share of votes, %
Simris Inc.	USD	6 888 086	Delaware, US	100	100
Simris Biologics GmbH	EUR	HRB 91773 B	Berlin, Germany	100	100

NOTE 10 | PREPAYMENTS AND ACCRUED INCOME

(kSEK)	The group		The parent company	
	2022	2021	2022	2021
Prepaid leasing fee	0	0	0	0
Prepaid premises rent	0	0	0	0
Prepaid wages	0	158	0	158
Prepaid cost suppliers	200	580	50	543
TOTAL PREPAID COSTS AND ACCRUED INCOME	200	738	50	701

NOTE 11 | SHARE CAPITAL

The share capital in Simris Group AB amounts to SEK 15,663,840.95 and is divided into 180,302,520 shares, of which 180,302,520B shares and 0 A shares. Each share has a quota value of SEK 0.0869.

NOTE 12 | LONG-TERM LIABILITIES

(kSEK)	The group		The parent company	
	2022	2021	2022	2021
Expires within 2 to 5 years	385	538	385	538
Expires later than 5 years	1,174	1,270	1,174	1,270
TOTAL LONG-TERM LIABILITIES	1,559	1,808	1,559	1,808

NOTE 13 | ACCRUED EXPENSES AND PREPAID INCOME

(kSEK)	The group		The parent company	
	2022	2021	2022	2021
Accrued wages	0	403	0	403
Accrued holiday pay	348	524	348	524
Accrued social security charges	197	210	197	210
Other accrued costs	651	906	584	879
TOTAL ACCRUED EXPENSES AND PREPAID INCOME	1,196	2,043	1,129	2,016

NOTE 14 | SIGNIFICANT EVENTS AFTER THE BALANCE SHEET DATE

- Launch of EU-approved Omega-3 supplement in Sweden.
- The flexible financing facility from related companies to Chairman of the Board Steven Schapera was increased from 1.0 to 1.5 million euros.
- The board held an extraordinary meeting on March 6, 2023 where the shareholders decided to change the company name Simris Alg AB to Simris Group AB. A decision was also made to accept the terms of the flexible financing facility from Chairman of the Board Steven Schapera.
- Upgrades of several systems at the production plant in Hammenhög took place during the winter and the start-up showed greatly improved production in the upgraded systems.
- The name change of the subsidiary Cyano Biotech GmbH to Simris Biologics GmbH has been carried out.
- Simris Biologics GmbH was granted a Japanese patent covering modification of microcystin.
- The subsidiary Simris Biologics GmbH signed a collaboration agreement with Lonza Ltd for the marketing of a patented ADC payload technology.

NOTE 15 | TRANSACTIONS WITH RELATED PARTIES AND GROUP COMPANIES

During 2022 and 2021, there have been no transactions with related parties that deviate from market conditions.

Chairman of the board Steven Schapera and board members Robert Quandt and Frank Puccio have participated in the company's bridging loan with SEK 1 million each. The bridging loan comprised a total of SEK 7 million and has been repaid in 2022. The loan had a set-up fee of 5 percent and the interest rate was 1 percent per month.

In connection with the company's rights issue, chairman of the board Steven Schapera and board members Robert Quandt and Frank Puccio issued guarantees of SEK 1m each, for which they were compensated with SEK 100,000.

Chairman of the board Steven Schapera has provided the

business with a flexible financing option of EUR 1.0 million that can be used if necessary. At the end of the financial year, 675 thousand euros had been used. The loan must be repaid no later than August 25, 2023.

The loan has a set-up fee of 2.5 percent and the interest rate is 1 percent per month. After the end of the financial year, the credit has been increased by 0.5 million euros and the company will hand over security in the form of corporate mortgages.

In addition to normal board work, during the year board members performed consulting services for the company that were invoiced, of which Steven Schapera SEK 1,011,000, Robert Quandt SEK 77,000, Frank Puccio SEK 103,000 and Magnus Högström SEK 37,000.

Compilation of transactions with group companies (kSEK)	The parent company	
	2022	2021
Sale of goods and services	0	1,158
The claim, including accrued interest	1,117	0
Accrued and capitalized interest	779	554

NOTE 16 | SECURITIES PROVIDED

Pledged collateral for own liabilities and provisions, (kSEK)	The group		The parent company	
	2022	2021	2022	2021
Corporate mortgages	6,000	6,000	6,000	6,000
Real estate mortgages	2,425	2,425	2,425	2,425
TOTAL SECURITIES PROVIDED FOR OWN LIABILITIES AND PROVISIONS	8,425	8,425	8,425	8,425

NOTE 17 | ACQUISITION OF BUSINESS

On 25 August 2022, Simris Group acquired 100 percent of the shares in the Berlin based company Cyano Biotech. Cyano Biotech is a leader in the field of cyanobacterial research. They hold what is likely to be the world's largest library of cyanobacteria, with >1,100 producer strains, and two strong patents covering the modification and use of cyanobacterial toxins as payloads within antibody drug conjugate (ADC) medicines.

Following the acquisition of Cyano Biotech, Simris now has its own research & development (R&D) laboratories and a team of research scientists plus a patent protected technology platform. This provides Simris with entrance into the highly valuable Bio-Pharma sector. The combined Simris/ Cyano Biotech business offers drug developers with an entirely unique proposition to design ADC payloads to be highly potent and highly specific. These are then to be produced ready to conjugate to monoclonal antibodies within growing cyanobacteria in our system of photo-bioreactors. Furthermore, Simris now holds a library of >5,000 novel molecules isolated from its cyanobacterial producer strains. Within this library are molecules that, amongst other applications, have shown potential for development as antimicrobials (novel antibiotics), antifungals, insecticides, plant growth stimulants, cosmetic ingredients and in age related diseases such as cancer and Alzheimer's.

The maximum acquisition price amounts to €10,323m. The deal includes two cash payments of €1m, the first of which was paid at closure of the deal, with the second €1m to be paid on the first anniversary of the date of the acquisition. In addition, the

two founders of Cyano Biotech will each receive two lots of Simris shares equivalent to the value of €60,000. The first instalment of shares was allocated on the day of acquisition with the second allocation being made upon the first anniversary of the date of acquisition. The number of shares allocated will be calculated based upon the vwap of the 5 days preceding the date of allocation. A further value of €8m can be paid through earn-outs from sales from the ADC platform at a rate of 10% of sales revenue generated from this platform. For the full value of €8m to be paid out Simris will need to make sales of €80m from the sales from ADC platform over the remaining 15 years and 8 months of the patents. The final element of the deal is that Simris will provide a 10% earn-out on Cyano Biotech's other product areas and outside of the ADC platform until the end of 2025. The value of this will be 10% of sales revenue and will be paid out in Simris shares. The number of shares will be calculated based upon the vwap of the 5 days preceding the date of allocation. The effect of the acquisition on the Group's cash and cash equivalents was SEK -10.1m. The acquisition analysis is preliminary.

Of the total intangible fixed assets, SEK 153 m relates to the patented ADC technology. As the potential for sales and associated profit over the remaining lifetime of the patents is believed to be greater than the level required to trigger the maximum earn-out, no goodwill was allocated. Acquisition-related costs amounted to SEK 0.5m and relate to fees paid to consultants in connection with the transaction, including due diligence and legal advice. These expenses have been charged to operating profit.

Acquisition price (kSEK)	
Transferred remuneration cash	10,682
Transferred remuneration issue shares	1,282
Payment august 2023 cash	10,682
Payment august 2023 shares	1,282
Provision additional purchase price	86,345
PURCHASE PRICE	110,273
Identifiable acquired assets and liabilities (kSEK)	
Intangible assets	153,052
Tangible assets	2,006
Inventory	1,998
Other receivables	260
Cash and bank balances	591
Deferred tax	-46,412
Short-term liabilities	-1,222
TOTAL IDENTIFIABLE NET ASSETS	110,273
Transferred remuneration cash	-10,682
Acquired cash and cash equivalents	591
EFFECT ON CONSOLIDATED CASH AND CASH EQUIVALENTS	-10,091
Net sales during holding time	120
Net sales 2022 before acquisition	1,059
Net profit during holding time	-175
Net profit 2022 before acquisition	3,028

NOTE 18 | PROPOSAL FOR DISPOSAL OF PROFITS

	Amount in SEK
Premium fund	73,051,265
Balanced result	-43,165,829
This year's results	-19,891,948
TOTAL	9,993,488
Disposed of in such a way that: in a new account is transferred	9,993,488
TOTAL	9,993,488

Hammenhög 17th April 2023

Steven Schapera
Chairman

Magnus Högström
Board Member

Frank Puccio
Board Member

Robert Quandt
Board member

Julian Read
Managing Director

Our audit report was issued on 17 April 2023
Ernst & Young AB

Peter Gunnarsson
Chartered Accountant

FINANCIAL DEFINITIONS

Balance Sheet

The sum of all assets on the balance sheet or the sum of all liabilities and equity.

Cash flow

Current assets excluding inventory and work in progress as a percentage of current liabilities.

Earnings per share

The period's result divided by the number of shares after the end of the period.

Earnings per share after full dilution

Profit for the period divided by the number of shares after the end of the period, taking into account after conversion and adjusted for the effect of share-related compensation.

Equity per share

Adjusted equity (equity and untaxed reserves including deduction for deferred tax) divided by the number of shares at the end of the period.

Equity per share after full dilution

Adjusted equity (equity and untaxed reserves less deferred tax) divided by the number of shares at the end of the period with consideration after conversion and adjusted for the effect of share-related compensation.

Net sales

The operation's main income, invoiced costs, side income and income corrections.

Operating results

Profit before financial costs and tax.

Profit before tax

Results after financial income and expenses, but before extraordinary income and expenses.

Solidity

Adjusted equity (equity and untaxed reserves less deferred tax) as a percentage of total assets.

AUDIT REPORT

To the general meeting of the shareholders of Simris Group AB, corporate identity number 556841-9187

REPORT ON THE ANNUAL ACCOUNTS AND CONSOLIDATED ACCOUNTS

Opinions

We have audited the annual accounts and consolidated accounts of Simris Group AB for the year 2022. The annual accounts and consolidated accounts of the company are included on pages 8–27 in this document.

In our opinion, the annual accounts and consolidated accounts have been prepared in accordance with the Annual Accounts Act and present fairly, in all material respects, the financial position of parent company and the group as of 31 December 2022 and their financial performance and cash flow for the year then ended in accordance with the Annual Accounts Act. The statutory administration report is consistent with the other parts of the annual accounts and consolidated accounts.

We therefore recommend that the general meeting of shareholders adopts the income statement and balance sheet for the parent company and the group.

Basis for Opinions

We conducted our audit in accordance with International Standards on Auditing (ISA) and generally accepted auditing standards in Sweden. Our responsibilities under those standards are further described in the Auditor's Responsibilities section. We are independent of the parent company and the group in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled our ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinions.

Significant uncertainties regarding the assumption of going concern

We would like to draw attention to the information provided on pages 12, 13 and 15 of the Annual Report and consolidated financial statements, where it is presented that the company reported a loss of kSEK 24,422 for the year ended 31 December, 2022, that cash flow after investment activities is negative by 40,570 kSEK for 2022 and that cash and cash equivalents amount to kSEK 3,994 as of 31 December 2022. These circumstances, together with other circumstances mentioned in the Liquidity risk and Future prospects sections of the Annual Report on pages 10–11, indicate that there are significant uncertainties that may lead to significant doubts about the entity's ability to continue its operations. We have not modified our statement because of this.

Other Information than the annual accounts and consolidated accounts

This document also contains other information than the annual accounts and consolidated accounts and is found on pages 1–7 and 30–34. The Board of Directors and the Managing Director are responsible for this other information.

Our opinion on the annual accounts and consolidated accounts does not cover this other information and we do not express any form of assurance conclusion regarding this other information.

In connection with our audit of the annual accounts and consolidated accounts, our responsibility is to read the information identified above and consider whether the information is

materially inconsistent with the annual accounts and consolidated accounts. In this procedure we also take into account our knowledge otherwise obtained in the audit and assess whether the information otherwise appears to be materially misstated.

If we, based on the work performed concerning this information, conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Board of Directors and the Managing Director

The Board of Directors and the Managing Director are responsible for the preparation of the annual accounts and consolidated accounts and that they give a fair presentation in accordance with the Annual Accounts Act. The Board of Directors and the Managing Director are also responsible for such internal control as they determine is necessary to enable the preparation of annual accounts and consolidated accounts that are free from material misstatement, whether due to fraud or error.

In preparing the annual accounts and consolidated accounts, The Board of Directors and the Managing Director are responsible for the assessment of the company's and the group's ability to continue as a going concern. They disclose, as applicable, matters related to going concern and using the going concern basis of accounting. The going concern basis of accounting is however not applied if the Board of Directors and the Managing Director intend to liquidate the company, to cease operations, or has no realistic alternative but to do so.

Auditor's responsibility

Our objectives are to obtain reasonable assurance about whether the annual accounts and consolidated accounts as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinions. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and generally accepted auditing standards in Sweden will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual accounts and consolidated accounts.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual accounts and consolidated accounts, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinions. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of the company's internal control relevant to our audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors and the Managing Director.

- Conclude on the appropriateness of the Board of Directors' and the Managing Director's use of the going concern basis of accounting in preparing the annual accounts and consolidated accounts. We also draw a conclusion, based on the audit evidence obtained, as to whether any material uncertainty exists related to events or conditions that may cast significant doubt on the company's and the group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the annual accounts and consolidated accounts or, if such disclosures are inadequate, to modify our opinion about the annual accounts and consolidated accounts. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause a company and a group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the annual accounts and consolidated accounts, including the disclosures, and whether the annual accounts and consolidated accounts represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient and appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated accounts. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our opinions.

We must inform the Board of Directors of, among other matters, the planned scope and timing of the audit. We must also inform of significant audit findings during our audit, including any significant deficiencies in internal control that we identified.

REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENTS

Opinions

In addition to our audit of the annual accounts and consolidated accounts, we have also audited the administration of the Board of Directors and the Managing Director of Simris Group AB for the year 2022 and the proposed appropriations of the company's profit or loss.

We recommend to the general meeting of shareholders that the profit be appropriated in accordance with the proposal in the statutory administration report and that the members of the Board of Directors and the Managing Director be discharged from liability for the financial year.

Basis for Opinions

We conducted the audit in accordance with generally accepted auditing standards in Sweden. Our responsibilities under those standards are further described in the Auditor's Responsibilities section. We are independent of the parent company and the group in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled our ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinions.

Responsibilities of the Board of Directors and the Managing Director

The Board of Directors is responsible for the proposal for appropriations of the company's profit or loss. At the proposal of a dividend, this includes an assessment of whether the dividend is

justifiable considering the requirements which the company's and the group's type of operations, size and risks place on the size of the parent company's and the group's equity, consolidation requirements, liquidity and position in general.

The Board of Directors is responsible for the company's organization and the administration of the company's affairs. This includes among other things continuous assessment of the company's and the group's financial situation and ensuring that the company's organization is designed so that the accounting, management of assets and the company's financial affairs otherwise are controlled in a reassuring manner. The Managing Director shall manage the ongoing administration according to the Board of Directors' guidelines and instructions and among other matters take measures that are necessary to fulfill the company's accounting in accordance with law and handle the management of assets in a reassuring manner.

Auditor's responsibility

Our objective concerning the audit of the administration, and thereby our opinion about discharge from liability, is to obtain audit evidence to assess with a reasonable degree of assurance whether any member of the Board of Directors or the Managing Director in any material respect:

- has undertaken any action or been guilty of any omission which can give rise to liability to the company, or
- in any other way has acted in contravention of the Companies Act, the Annual Accounts Act or the Articles of Association.

Our objective concerning the audit of the proposed appropriations of the company's profit or loss, and thereby our opinion about this, is to assess with reasonable degree of assurance whether the proposal is in accordance with the Companies Act.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with generally accepted auditing standards in Sweden will always detect actions or omissions that can give rise to liability to the company, or that the proposed appropriations of the company's profit or loss are not in accordance with the Companies Act.


As part of an audit in accordance with generally accepted auditing standards in Sweden, we exercise professional judgment and maintain professional skepticism throughout the audit. The examination of the administration and the proposed appropriations of the company's profit or loss is based primarily on the audit of the accounts. Additional audit procedures performed are based on our professional judgment with starting point in risk and materiality. This means that we focus the examination on such actions, areas and relationships that are material for the operations and where deviations and violations would have particular importance for the company's situation. We examine and test decisions undertaken, support for decisions, actions taken and other circumstances that are relevant to our opinion concerning discharge from liability. As a basis for our opinion on the Board of Directors' proposed appropriations of the company's profit or loss we examined whether the proposal is in accordance with the Companies Act.

Malmö 17th April 2023
Ernst & Young AB

Peter Gunnarsson
Chartered Accountant

OUR BOARD OF DIRECTORS

According to the articles of association, Simris Group's board must consist of a minimum of three and a maximum of seven members without deputies.



Steven Schapera
Chairman

Born: 1960

Previous experience: Founder of BECCA Cosmetics in 2001 which was later acquired by Estée Lauder in 2016. Operating Partner for the Private Equity investor in Invincible Brands, sold to Henkel 2020. Chairman of ASX-listed Unith Ltd. to June 30 2022.

Other assignments: Steven is chairman of London Stock Exchange listed Tertre Rouge Assets Plc, Founder and CEO of NYSE-listed Integrated Wellness Acquisition Corp. Board member Wild Nutrition Ltd.

Steven Schapera is independent in relation to Simris and the company management and major shareholders in the company.

Holdings: 9,098,697 B-shares, 640,000 warrants.



Robert Quandt
Board Member

Born: 1979

Previous experience: Robert was CFO and COO of Invincible Brands which developed new brands in health and beauty and which was sold to Private Equity in 2017 and Henkel 2020. Previous to this Robert was a consultant at Booz & Company and Senior Strategy Manager at Linde AG responsible for the strategy in North and South America.

Other assignments: Today Robert is CFO of Les Lunes, a fashion brand, and co-founder of Integrated Wellness Acquisition Corp (SPAC).

Robert Quandt is independent in relation to Simris, the company management and major shareholders in the company.

Holdings: 3,212,697 B-shares, 340,000 warrants.



Magnus Högström
Board Member

Born: 1973

Previous experience: Magnus has a background in fund management and market analytics working with, amongst others, Adelphi Capital and SEB.

Other assignments: Magnus is a Board Member of HStream Invest.

Magnus Högström is independent in relation to Simris and the company management and not independent of major shareholders in the company.

Holdings: 2,500,000 B-shares, 570,000 warrants.



Frank Puccio
Board Member

Born: 1956

Previous experience: Frank is a biologist and pharmacist by early training and graduated from Cornell University College of Veterinary Medicine. Frank purchased a veterinary clinic which he and his team grew into the largest 24/7 full service veterinary hospital in his area. He was a founding member/officer in a nationwide veterinary hospital group, Companion Animal Practices North America (CAPNA), which subsequently grew into a group of over 80 veterinary hospitals.

Other assignments: Today Frank is an advisor to HW&B Enterprises working with aloe vera based products in nutrition, skin care and anti-inflammatory applications.

Frank Puccio is independent in relation to Simris, the company management and major shareholders in the company.

Holdings: 3,212,697 B-shares, 340,000 warrants.

Auditor

Our auditor is **Peter Gunnarsson**, authorized auditor, EY.

OUR MANAGEMENT

The management team consists of CEO Julian Read, CFO Christoffer Tell and Production Manager Hannes Hall.



Julian Read
CEO

Born: 1972

Previous experience: Julian has a BSc in Biological Science from the University of Warwick, England. Julian has extensive sales & marketing experience in rapid diagnostics, skin care, home electronics, footwear and over the counter medicines having worked in leading roles for Unilever, Reckitt Benckiser, Perrigo & Dyson.

Other assignments: None.

Holdings: 3,500,000 warrants.



Christoffer Tell
CFO

Born: 1987

Previous experience: Christoffer has over 10 years of experience in leading roles across different industry sectors. Previous to Simris Christoffer held the position of CFO for Global Gaming and CFO for Examec Group. Today he works as an independent consultant and auditor.

Other assignments: Christoffer Tell AB - Board member. CORMKA AB - Chairman. Mainstream Media Scandinavia AB - Chairman, CEO. Simrishamns Låsservice AB - Board deputy. Newbury Pharmaceuticals AB - CFO.

Holdings: 800,000 B-shares, 430,000 warrants.



Hannes Hall
Production Manager

Born: 1987

Previous experience: Hannes holds an MSc in Biology from Lund university and has experience of leading roles from several branches of industry.

Other assignments: None.

Holdings: 1,600 B-shares, 200,000 warrants.

THE SHARE

Simris Group's B share has been listed on Nasdaq First North since April 22, 2016 under the ticker SIMRIS.

The highest payment rate in 2022 was noted at SEK 0.908 on January 4 and the lowest payment rate was noted at SEK 0.238 on June 17. A total of approximately 59 (95) million shares were traded during the year, an average of 233,362 shares (377,450) per trading day.

The stock and the owners

At the turn of the year, the share capital amounted to SEK 15,663,841 distributed over 180,302,520 shares, of which 180,302,500 B shares and 0 A shares. All shares have a quota value of SEK 0.0869. Each B share gives the right to one vote and each A share gives the right to two votes. The A shares are unlisted and subject to conversion clauses which mean that they can be converted into B shares at the owner's request. Both types of shares give equal rights to a share in the company's assets, profits and dividends. On December 31, 2022, the company had 6,534 shareholders (6,709), of which the ten largest owned 29.53 percent of the share capital and votes.

Option program

Simris Group had five outstanding option programs at the turn of the year. The terms have been recalculated according to the new issues carried out after the issue of the options up to and including the reporting period. Full utilization of all outstanding warrants corresponds to a dilution of 5.5 percent.

10 LARGEST SHAREHOLDERS

Owner 2022-12-31	Holding %
Avanza Pension	7.34
Six Sis Ag, W8imy	5.25
Johansson, Bengt	3.45
Nordnet Pensionsförsäkring AB	2.46
Pension, Futur	2.41
Aqurat Fondkommission AB	2.18
Deutsche Bank Ag, W8imy	1.89
Cbny-National Financial Services LI	1.78
Högström, Magnus	1.39
Euroclear Bank S.a/N.v, W8-lmy	1.38
Total of the 10 largest shareholders	29.53
Other	70.47
Total	100.00

Source: Euroclear

CHANGE IN SHARE CAPITAL

Time	Event	Price per share SEK	Change in number of shares		Shares after transaction			Share capital SEK	
			A-shares	B-shares	A-shares	B-shares	Total number of shares	Change SEK	Total SEK
2011	Formation	5		10,000		10,000	10,000	50,000	50,000
2012	Rights issue	800		5,250		15,250	15,250	26,250	76,250
2012	Conversion	N/A	2,500	-2,500	2,500	12,750	15,250	N/A	76,250
2012	Rights issue	800		5,850	2,500	18,600	21,100	29,250	105,500
2013	Rights issue	800		1,875	2,500	20,475	22,975	9,375	114,875
2013	Rights issue	800		625	2,500	21,100	23,600	3,125	118,000
2013	Rights issue	800		625	2,500	21,725	24,225	3,125	121,125
2013	Rights issue	800		1,250	2,500	22,975	25,475	6,250	127,375
2014	Rights issue	981		11,097	2,500	34,072	36,572	55,485	182,860
2014	Rights issue	981		2,265	2,500	36,337	38,837	11,325	194,185
2014	Rights issue	981		554	2,500	36,891	39,391	2,770	196,955
2015	Rights issue	1,270		8,700	2,500	45,591	48,091	43,500	240,455
2015	Rights issue	1,588		3,001	2,500	48,592	51,092	15,005	255,460
2015	Rights issue	1,588		16,704	2,500	65,296	67,796	83,520	338,980
2015	Bonus issue	N/A		N/A	2,500	65,296	67,796	250,000	588,980
2015	Split 100:1	N/A	247,500	6,512,896	250,000	6,529,600	6,779,600	N/A	588,980
2016	Rights issue	18.5		2,720,400	250,000	9,250,000	9,500,000	236,336	825,316
2018	Rights issue	8.51		87,788	250,000	9,337,788	9,587,788	7,626	832,942
2018	Rights issue	8.71		86,324	250,000	9,424,112	9,674,112	7,499	840,442
2018	Rights issue	6.5		3,769,644	250,000	13,193,756	13,443,756	327,489	1,167,931
2019	Rights issue	8.08		26,676	250,000	13,220,432	13,470,432	2,318	1,170,249
2019	Rights issue	3.5		8,066,256	250,000	21,286,688	21,536,688	700,759	1,871,007
2020	Rights issue	0.9		32,305,032	250,000	53,591,720	53,841,720	2,806,510	4,677,517
2020	Rights issue	0.9		3,162,286	250,000	56,754,006	57,004,006	274,724	4,952,241
2020	Rights issue	0.59		21,536,688	250,000	78,290,694	78,540,694	1,871,007	6,823,248
2021	Rights issue	3.33		6,352	250,000	78,297,046	78,547,046	552	6,823,801
2022	Conversion	N/A	-250,000	250,000	0	78,547,046	78,547,046	N/A	6,823,801
2022	Rights issue	0.32		78,547,046	0	157,094,092	157,094,092	6,823,801	13,647,601
2022	Rights issue	0.32		19,276,182	0	176,370,274	176,370,274	1,674,625	15,322,226
2022	Rights issue	0.31635		3,932,246	0	180,302,520	180,302,520	341,615	15,663,841




THE ANNUAL REPORT

For environmental reasons, Simris Group distributes the annual report and other general meeting documents only in digital format on the website simrisgroup.com. Shareholders who so request can receive a printed version if they request it and state their address.

MEDIA CONTACT:

Julian Read, CEO
 Tel: +46 (0)767 88 82 12
 Email: IR@simris.com

READ MORE ABOUT US AT:



simrisgroup.com

FOLLOW US ON:



© SIMRIS GROUP AB (PUBL) • PIONEERING ALGAE BIOTECH SINCE 2011
+46(0)414-44 50 50 • INFO@SIMRIS.COM • WWW.SIMRISGROUP.COM
HERRESTADSVÄGEN 24A, 276 50 HAMMENHÖG, SWEDEN

Simris
GROUP

© 2023 Simris Group AB